What is Hemab Therapeutics Holdings worth?
$386.9Mlast known valuation
Hemab Therapeutics Holdings last raised $157.0M in its Later Stage VC (Series C) (Oct 2025).
Free account
See the evidence behind this price
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 12 names
- ·Watchlist + deal alerts for Hemab Therapeutics Holdings
Create free account
No card required
Funding history
2 rounds| Date | Round | Raised | Post-money | $/share |
|---|---|---|---|---|
| Oct 2025 | Later Stage VC (Series C) | $157.0M | ▮ | ▮ |
| Feb 2023 | Early Stage VC (Series B) | $137.8M | ▮ | ▮ |
How Hemab Therapeutics Holdings's valuation is determined
Private company valuations aren’t quoted on an exchange — they’re established in moments: a priced funding round sets a post-money valuation, secondary trades print at a price per share, and SEC-registered funds holding the stock report fair-value marks in their N-PORT filings.
For Hemab Therapeutics Holdings, we compose those signals into the PA Mark — a weighted composite of 3 recent pricing inputs, decayed by age and reset on new rounds. The implied valuation multiplies the mark by shares outstanding. Full methodology →
Frequently asked
- What is Hemab Therapeutics Holdings worth?
- Hemab Therapeutics Holdings's implied valuation is $386.9M, based on the PA Mark composite price of about $29 per share as of Sep 2026.
- How much has Hemab Therapeutics Holdings raised?
- Hemab Therapeutics Holdings has raised $355.1M in total funding across 2 recorded rounds.
- When did Hemab Therapeutics Holdings last raise?
- Hemab Therapeutics Holdings last raised in Oct 2025 (Later Stage VC (Series C)), raising $157.0M.